Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Trial of WP1066 in Patients With Recurrent Malignant Glioma and Brain Metastasis From Melanoma

Trial Profile

A Phase I Trial of WP1066 in Patients With Recurrent Malignant Glioma and Brain Metastasis From Melanoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2018

At a glance

  • Drugs WP 1066 (Primary)
  • Indications Brain metastases; Glioblastoma; Glioma; Malignant melanoma
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 01 Nov 2018 According to a Moleculin Biotech media release, company announced positive progress in this trial with initial results showing bioavailability of the drug in patients.
    • 05 Oct 2018 Planned End Date changed from 1 Jul 2022 to 1 Jul 2021.
    • 13 Sep 2018 According to a Moleculin Biotech media release, the first patient has been dosed in this study. The company is intended to eventually treat up to 15 relapsed brain cancer patients over the next six to eight months.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top